Climb Bio, Inc(CLYM) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the Coming Weeks • Continued development of subcutaneous (SC) formulation. Climb Bio obtained supportive non-clinical data for its budoprutug SC formulation, which demonstrated high bioavailability and favorable toler ...